CSIMarket Company Name, Ticker, Competitors, else..
 
Beyondspring Inc   (NASDAQ: BYSI)
 
Price: $0.6205 $-0.04 -6.692%
Day's High: $0.6625000238418579 Week Perf: -13.82 %
Day's Low: $ 0.61 30 Day Perf: -46.04 %
Volume (M): 55,840 52 Wk High: $ 2.44
Volume (M$): $ 0 52 Wk Avg: $1.60
Open: $0.64 52 Wk Low: $0.57



 Market Capitalization (Millions $) 26
 Shares Outstanding (Millions) 41
 Employees 44
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 0

Business Description


Beyondspring Inc is a clinical-stage pharmaceutical company that focuses on the development of innovative cancer therapies. The company is involved in discovering and developing novel immuno-oncology drugs to improve the outcomes of cancer patients. Beyondspring's drug candidates are designed to target specific mechanisms within the immune system to enhance anti-cancer response and reduce the relapse rate. Their flagship product, Plinabulin, has shown promising results in clinical trials for the treatment of various types of cancers, including non-small cell lung cancer and triple-negative breast cancer. Beyondspring Inc is dedicated to bringing new treatment options to patients and improving cancer care worldwide.


   Company Address: 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park 7932 NJ
   Company Phone Number: 305-6387   Stock Exchange / Ticker: NASDAQ BYSI


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Augmenting Metastatic NSCLC Treatment New Hope with a Triple Immunotherapy Approach Post-Checkpoint Inhibition...

Published Mon, Nov 11 2024 1:00 PM UTC

The treatment landscape for metastatic non-small cell lung cancer (NSCLC) has significantly evolved with the advent of immune checkpoint inhibitors (ICIs). Despite initial efficacy, resistance often follows treatment, necessitating novel therapeutic approaches. BeyondSpring s recent study presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting invest...
Clinical Study

“Revolutionizing NSCLC Treatment Plinabulin/Docetaxel Combination Offers Enhanced Survival and Quality of Life

Published Mon, Sep 16 2024 11:00 AM UTC

Revolutionizing NSCLC Treatment: Plinabulin/Docetaxel Combination Offers Enhanced Survival and Quality of LifeAt the forefront of oncological research, BeyondSpring Pharmaceuticals has unveiled promising final data from its DUBLIN-3 Phase 3 clinical study, presented at the ESMO Congress 2024. This pivotal study is set to redefine treatment paradigms for patients grappling w...
Clinical Study

Advancing Oncology BeyondSprings Promising Phase 3 Findings for Plinabulin in EGFR Wild-Type NSCLC

Published Tue, Sep 10 2024 11:00 AM UTC

BeyondSpring Inc. recently delivered a significant oral presentation at the ISLAC 2024 World Conference on Lung Cancer, highlighting the final Phase 3 data for its lead anti-cancer asset, Plinabulin, in the context of second-line (2L) and third-line (3L) non-small cell lung cancer (NSCLC) among EGFR wild-type patients. Alongside the presentation, critical findings were conc...
Partnership

Innovative Partnership SEED Therapeutics and Eisai Join Forces to Elevate Therapeutics for Neurodegeneration an...

Published Tue, Aug 6 2024 11:00 AM UTC

In a significant advancement in the realm of drug discovery, SEED Therapeutics, a pioneering biotechnology company, has announced a strategic research collaboration with Eisai Co., Ltd. This collaboration is aimed at discovering and developing novel molecular glue degraders for treating neurodegenerative diseases and various oncology indications. Concurrently, SEED has se...
Clinical Study

New Plinabulin Development Strategy and SEED Therapeutics Update: BeyondSpring's Promising Advances in Cancer Treatment

Published Thu, May 16 2024 12:00 PM UTC

BeyondSpring Inc., a clinical-stage global biopharmaceutical company specializing in innovative cancer therapies, recently held a virtual Research and Development (R&D) Day to highlight its latest breakthroughs. The event focused on discussing the potential of Plinabulin, the Company s lead asset, as a dendritic cell (DC) maturation agent in combination with other drugs to a...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.43
Working Capital Ratio 0.57
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.16 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.25 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -525,273
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.